ABSTRACT… Background: Profound reduction in antegrade epicardial coronary flow with concomitant ischemia is seen occasionally during percutaneous coronary intervention despite the absence of evident vessel dissection, obstruction, or distal vessel embolic cutoff. Study Design: Descriptive study. Setting: Khatum-un-Nabyeen Heart Center for percutaneous coronary intervention. Period: January 2016 and December 2016. Methods and Results: Both males and females with age 30 years or more, presented. Patients with coronary angiograms suggestive of percutaneous coronary intervention were included in the study by using nonprobability, purposive sampling technique. Following ethical and research approval from the hospital administration, clinical profile of the patients was documented. Patients presented with acute coronary syndrome as well as patients with stable coronary artery disease requiring coronary intervention based on clinical, ECG, non-invasive test or coronary angiogram were enrolled in the study. Patients with previous history of PCI or CABG were also included in the study. Pregnant patients were excluded from the study. The objective of this study is to find out the incidence of no reflow phenomenon during PCI in our population. The TIMI flow grade was determined for each treated vessel. The criteria for no-reflow was development of substantial flow reduction (less than TIMI 3 flow) in the absence of apparent dissection, thrombosis, or distal vessel cutoff suggestive of macroembolization. SPSS version 16.0 was used for analyzing the data. Frequency and percentages were used for categorical variables. Mean±SD was used for numerical variables. Data were presented in the form of tables. Conclusions: The no-reflow phenomenon, reduction in distal flow without apparent dissection or distal embolization -occurs in 2.25% of coronary interventions.
Background: Profound reduction in antegrade epicardial coronary flow withconcomitant ischemia is seen occasionally during percutaneous coronary intervention despitethe absence of evident vessel dissection, obstruction, or distal vessel embolic cutoff. StudyDesign: Descriptive study. Setting: Khatum-un-Nabyeen Heart Center for percutaneouscoronary intervention. Period: January 2016 and December 2016. Methods and Results: Bothmales and females with age 30 years or more, presented. Patients with coronary angiogramssuggestive of percutaneous coronary intervention were included in the study by using nonprobability,purposive sampling technique. Following ethical and research approval from thehospital administration, clinical profile of the patients was documented. Patients presentedwith acute coronary syndrome as well as patients with stable coronary artery disease requiringcoronary intervention based on clinical, ECG, non-invasive test or coronary angiogram wereenrolled in the study. Patients with previous history of PCI or CABG were also included in thestudy. Pregnant patients were excluded from the study. The objective of this study is to find outthe incidence of no reflow phenomenon during PCI in our population. The TIMI flow grade wasdetermined for each treated vessel. The criteria for no-reflow was development of substantialflow reduction (less than TIMI 3 flow) in the absence of apparent dissection, thrombosis, ordistal vessel cutoff suggestive of macroembolization. SPSS version 16.0 was used for analyzingthe data. Frequency and percentages were used for categorical variables. Mean±SD was usedfor numerical variables. Data were presented in the form of tables. Conclusions: The no-reflowphenomenon, reduction in distal flow without apparent dissection or distal embolization - occursin 2.25% of coronary interventions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.